Novartis AG (NVS) Stock Competitors & Peer Comparison
See (NVS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVS | $155.41 | +0.19% | 296.3B | 17.87 | $8.69 | +3.05% |
| LLY | $1,208.12 | +7.13% | 1.1T | 41.01 | $29.42 | +0.54% |
| JNJ | $254.66 | +3.99% | 612.8B | 23.07 | $11.03 | +2.07% |
| ABBV | $251.52 | +3.45% | 445.2B | 24.73 | $10.19 | +2.74% |
| MRK | $128.38 | +2.34% | 317.1B | 23.47 | $5.47 | +2.64% |
| AZN | $188.41 | +1.47% | 292.1B | 20.34 | $9.26 | +1.70% |
| NVO | $48.07 | +0.90% | 213.5B | 11.92 | $4.03 | +3.78% |
| AMGN | $358.33 | +1.56% | 193.4B | 16.21 | $22.10 | +2.76% |
| GILD | $127.88 | +3.26% | 158.8B | 15.28 | $8.37 | +2.56% |
| PFE | $24.29 | +2.62% | 138.5B | 7.94 | $3.06 | +7.11% |
Stock Comparison
NVS vs LLY Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, NVS is priced at $155.41, while LLY trades at $1,208.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas LLY's P/E ratio is 41.01. In terms of profitability, NVS's ROE is +0.32%, compared to LLY's ROE of +1.01%. Regarding short-term risk, NVS is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check LLY's competition here
NVS vs JNJ Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, JNJ has a market cap of 612.8B. Regarding current trading prices, NVS is priced at $155.41, while JNJ trades at $254.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas JNJ's P/E ratio is 23.07. In terms of profitability, NVS's ROE is +0.32%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, NVS is less volatile compared to JNJ. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check JNJ's competition here
NVS vs ABBV Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, ABBV has a market cap of 445.2B. Regarding current trading prices, NVS is priced at $155.41, while ABBV trades at $251.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas ABBV's P/E ratio is 24.73. In terms of profitability, NVS's ROE is +0.32%, compared to ABBV's ROE of +0.68%. Regarding short-term risk, NVS is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check ABBV's competition here
NVS vs MRK Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, MRK has a market cap of 317.1B. Regarding current trading prices, NVS is priced at $155.41, while MRK trades at $128.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas MRK's P/E ratio is 23.47. In terms of profitability, NVS's ROE is +0.32%, compared to MRK's ROE of +0.18%. Regarding short-term risk, NVS is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check MRK's competition here
NVS vs AZN Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, AZN has a market cap of 292.1B. Regarding current trading prices, NVS is priced at $155.41, while AZN trades at $188.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas AZN's P/E ratio is 20.34. In terms of profitability, NVS's ROE is +0.32%, compared to AZN's ROE of +0.22%. Regarding short-term risk, NVS is less volatile compared to AZN. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check AZN's competition here
NVS vs NVO Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, NVO has a market cap of 213.5B. Regarding current trading prices, NVS is priced at $155.41, while NVO trades at $48.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas NVO's P/E ratio is 11.92. In terms of profitability, NVS's ROE is +0.32%, compared to NVO's ROE of +0.66%. Regarding short-term risk, NVS is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check NVO's competition here
NVS vs AMGN Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, AMGN has a market cap of 193.4B. Regarding current trading prices, NVS is priced at $155.41, while AMGN trades at $358.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas AMGN's P/E ratio is 16.21. In terms of profitability, NVS's ROE is +0.32%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, NVS is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check AMGN's competition here
NVS vs GILD Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, GILD has a market cap of 158.8B. Regarding current trading prices, NVS is priced at $155.41, while GILD trades at $127.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas GILD's P/E ratio is 15.28. In terms of profitability, NVS's ROE is +0.32%, compared to GILD's ROE of +0.42%. Regarding short-term risk, NVS is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check GILD's competition here
NVS vs PFE Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, PFE has a market cap of 138.5B. Regarding current trading prices, NVS is priced at $155.41, while PFE trades at $24.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas PFE's P/E ratio is 7.94. In terms of profitability, NVS's ROE is +0.32%, compared to PFE's ROE of +0.08%. Regarding short-term risk, NVS is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check PFE's competition here
NVS vs BMY Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, BMY has a market cap of 117.4B. Regarding current trading prices, NVS is priced at $155.41, while BMY trades at $57.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas BMY's P/E ratio is 9.70. In terms of profitability, NVS's ROE is +0.32%, compared to BMY's ROE of +0.39%. Regarding short-term risk, NVS is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check BMY's competition here
NVS vs GSK Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, GSK has a market cap of 105.3B. Regarding current trading prices, NVS is priced at $155.41, while GSK trades at $52.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas GSK's P/E ratio is 12.06. In terms of profitability, NVS's ROE is +0.32%, compared to GSK's ROE of +0.28%. Regarding short-term risk, NVS is less volatile compared to GSK. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check GSK's competition here
NVS vs SNY Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, SNY has a market cap of 103.3B. Regarding current trading prices, NVS is priced at $155.41, while SNY trades at $42.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas SNY's P/E ratio is 9.36. In terms of profitability, NVS's ROE is +0.32%, compared to SNY's ROE of +0.11%. Regarding short-term risk, NVS is less volatile compared to SNY. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check SNY's competition here
NVS vs ZTS Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, ZTS has a market cap of 31.9B. Regarding current trading prices, NVS is priced at $155.41, while ZTS trades at $76.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas ZTS's P/E ratio is 11.76. In terms of profitability, NVS's ROE is +0.32%, compared to ZTS's ROE of +0.62%. Regarding short-term risk, NVS is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check ZTS's competition here
NVS vs BIIB Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, BIIB has a market cap of 31.9B. Regarding current trading prices, NVS is priced at $155.41, while BIIB trades at $216.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas BIIB's P/E ratio is 13.64. In terms of profitability, NVS's ROE is +0.32%, compared to BIIB's ROE of +0.08%. Regarding short-term risk, NVS is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check BIIB's competition here
NVS vs HZNP Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, NVS is priced at $155.41, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas HZNP's P/E ratio is 61.86. In terms of profitability, NVS's ROE is +0.32%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, NVS is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for NVS.Check HZNP's competition here
NVS vs GRFS Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, GRFS has a market cap of 6.3B. Regarding current trading prices, NVS is priced at $155.41, while GRFS trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas GRFS's P/E ratio is 8.49. In terms of profitability, NVS's ROE is +0.32%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, NVS is more volatile compared to GRFS. This indicates potentially higher risk in terms of short-term price fluctuations for NVS.Check GRFS's competition here
NVS vs OGN Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, OGN has a market cap of 3.5B. Regarding current trading prices, NVS is priced at $155.41, while OGN trades at $13.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas OGN's P/E ratio is 4.03. In terms of profitability, NVS's ROE is +0.32%, compared to OGN's ROE of +0.30%. Regarding short-term risk, NVS is more volatile compared to OGN. This indicates potentially higher risk in terms of short-term price fluctuations for NVS.Check OGN's competition here
NVS vs CELG-RI Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, CELG-RI has a market cap of 183.8M. Regarding current trading prices, NVS is priced at $155.41, while CELG-RI trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.32%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, NVS is more volatile compared to CELG-RI. This indicates potentially higher risk in terms of short-term price fluctuations for NVS.Check CELG-RI's competition here
NVS vs SCLX Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, SCLX has a market cap of 60.4M. Regarding current trading prices, NVS is priced at $155.41, while SCLX trades at $7.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas SCLX's P/E ratio is -0.18. In terms of profitability, NVS's ROE is +0.32%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, NVS is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check SCLX's competition here
NVS vs CTOR Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, CTOR has a market cap of 57.6M. Regarding current trading prices, NVS is priced at $155.41, while CTOR trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas CTOR's P/E ratio is -1.32. In terms of profitability, NVS's ROE is +0.32%, compared to CTOR's ROE of -0.99%. Regarding short-term risk, NVS is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check CTOR's competition here
NVS vs MIRA Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, MIRA has a market cap of 42.4M. Regarding current trading prices, NVS is priced at $155.41, while MIRA trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas MIRA's P/E ratio is -0.70. In terms of profitability, NVS's ROE is +0.32%, compared to MIRA's ROE of -1.41%. Regarding short-term risk, NVS is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check MIRA's competition here
NVS vs SCLXW Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, SCLXW has a market cap of 40.5M. Regarding current trading prices, NVS is priced at $155.41, while SCLXW trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas SCLXW's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.32%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, NVS is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check SCLXW's competition here
NVS vs SRXH Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, SRXH has a market cap of 3.1M. Regarding current trading prices, NVS is priced at $155.41, while SRXH trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas SRXH's P/E ratio is -0.07. In terms of profitability, NVS's ROE is +0.32%, compared to SRXH's ROE of +8.75%. Regarding short-term risk, NVS is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check SRXH's competition here
NVS vs BDSIW Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, NVS is priced at $155.41, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas BDSIW's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.32%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, NVS is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check BDSIW's competition here
NVS vs CRXT Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 296.3B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, NVS is priced at $155.41, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 17.87, whereas CRXT's P/E ratio is -0.02. In terms of profitability, NVS's ROE is +0.32%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, NVS is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check CRXT's competition here